Barr Labs, For A Cheap Drug Buy

Although things are looking up for Barr Laboratories (BRL), two forces are working against its stock: It is a small-cap issue, and the company is in generic drugs. Both have been out of favor for some time. No matter, says money manager Michael Connor, who runs C-B Partners, a New York hedge fund. He sees small caps picking up soon and Barr shining as drug stocks emerge from the shadows.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.